MovDisordV3, PascalFrancis, Corpus, bibRecord, 000A86

Skin Cancer and Parkinson's Disease

Identifieur interne : 000A86 ( PascalFrancis/Corpus ); précédent : 000A85; suivant : 000A87

Skin Cancer and Parkinson's Disease

Auteurs : Joaquim J. Ferreira ; Dulce Neutel ; Tiago Mestre ; Miguel Coelho ; Mário M. Rosa ; Olivier Rascol ; Cristina Sampaio

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0303300

Descripteurs français

Pascal (Inist)
- Cancer de la peau, Maladie de Parkinson, Tumeur maligne, Mélanome malin, Pathologie du système nerveux, Pathologie de la peau, Peau.

English descriptors

KwdEn :
- Malignant melanoma, Malignant tumor, Nervous system diseases, Parkinson disease, Skin, Skin cancer, Skin disease.

Abstract

The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Skin Cancer and Parkinson's Disease`
A11	`01`	`1`		`@1 FERREIRA (Joaquim J.)`
A11	`02`	`1`		`@1 NEUTEL (Dulce)`
A11	`03`	`1`		`@1 MESTRE (Tiago)`
A11	`04`	`1`		`@1 COELHO (Miguel)`
A11	`05`	`1`		`@1 ROSA (Mário M.)`
A11	`06`	`1`		`@1 RASCOL (Olivier)`
A11	`07`	`1`		`@1 SAMPAIO (Cristina)`
A14	`01`			`@1 Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine @2 Lisbon @3 PRT @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut.`
A14	`02`			`@1 Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital @2 Toulouse @3 FRA @Z 6 aut.`
A20				`@1 139-148`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000170495040010`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 54 ref.`
A47	`01`	`1`		`@0 10-0303300`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Cancer de la peau @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Skin cancer @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Cáncer de piel @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Mélanome malin @5 04`
C03	`04`	`X`	`ENG`	`@0 Malignant melanoma @5 04`
C03	`04`	`X`	`SPA`	`@0 Melanoma maligno @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Pathologie de la peau @5 09`
C03	`06`	`X`	`ENG`	`@0 Skin disease @5 09`
C03	`06`	`X`	`SPA`	`@0 Piel patología @5 09`
C03	`07`	`X`	`FRE`	`@0 Peau @5 10`
C03	`07`	`X`	`ENG`	`@0 Skin @5 10`
C03	`07`	`X`	`SPA`	`@0 Piel @5 10`
C07	`01`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`01`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`01`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 193`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0303300 INIST
ET :	Skin Cancer and Parkinson's Disease
AU :	FERREIRA (Joaquim J.); NEUTEL (Dulce); MESTRE (Tiago); COELHO (Miguel); ROSA (Mário M.); RASCOL (Olivier); SAMPAIO (Cristina)
AF :	Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine/Lisbon/Portugal (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 7 aut.); Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital/Toulouse/France (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 2; Pp. 139-148; Bibl. 54 ref.
LA :	Anglais
EA :	The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.
CC :	002B17; 002B17G
FD :	Cancer de la peau; Maladie de Parkinson; Tumeur maligne; Mélanome malin; Pathologie du système nerveux; Pathologie de la peau; Peau
FG :	Cancer; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Skin cancer; Parkinson disease; Malignant tumor; Malignant melanoma; Nervous system diseases; Skin disease; Skin
EG :	Cancer; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Cáncer de piel; Parkinson enfermedad; Tumor maligno; Melanoma maligno; Sistema nervioso patología; Piel patología; Piel
LO :	INIST-20953.354000170495040010
ID :	10-0303300

Links to Exploration step

Pascal:10-0303300

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Skin Cancer and Parkinson's Disease</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="02"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0303300</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0303300 INIST</idno>
<idno type="RBID">Pascal:10-0303300</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Skin Cancer and Parkinson's Disease</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="02"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Malignant melanoma</term>
<term>Malignant tumor</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Skin</term>
<term>Skin cancer</term>
<term>Skin disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la peau</term>
<term>Maladie de Parkinson</term>
<term>Tumeur maligne</term>
<term>Mélanome malin</term>
<term>Pathologie du   système nerveux</term>
<term>Pathologie de la peau</term>
<term>Peau</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Skin Cancer and Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FERREIRA (Joaquim J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NEUTEL (Dulce)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MESTRE (Tiago)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>COELHO (Miguel)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ROSA (Mário M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA14 i1="01"><s1>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>139-148</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000170495040010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>54 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0303300</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cancer de la peau</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Skin cancer</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cáncer de piel</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mélanome malin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant melanoma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Melanoma maligno</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Peau</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Skin</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Piel</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>193</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0303300 INIST</NO>
<ET>Skin Cancer and Parkinson's Disease</ET>
<AU>FERREIRA (Joaquim J.); NEUTEL (Dulce); MESTRE (Tiago); COELHO (Miguel); ROSA (Mário M.); RASCOL (Olivier); SAMPAIO (Cristina)</AU>
<AF>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine/Lisbon/Portugal (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 7 aut.); Departments of Clinical Pharmacology and Neurosciences, INSERM CIC-9302 and UMR-825, University Hospital/Toulouse/France (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 2; Pp. 139-148; Bibl. 54 ref.</SO>
<LA>Anglais</LA>
<EA>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.</EA>
<CC>002B17; 002B17G</CC>
<FD>Cancer de la peau; Maladie de Parkinson; Tumeur maligne; Mélanome malin; Pathologie du   système nerveux; Pathologie de la peau; Peau</FD>
<FG>Cancer; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Skin cancer; Parkinson disease; Malignant tumor; Malignant melanoma; Nervous system diseases; Skin disease; Skin</ED>
<EG>Cancer; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Cáncer de piel; Parkinson enfermedad; Tumor maligno; Melanoma maligno; Sistema nervioso patología; Piel patología; Piel</SD>
<LO>INIST-20953.354000170495040010</LO>
<ID>10-0303300</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A86 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0303300
   |texte=   Skin Cancer and Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Skin Cancer and Parkinson's Disease

Skin Cancer and Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri